MARKETS

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira ® (adalimumab)

Kgaogelo MatshwiKgaogelo Matshwi
Apr 30, 2024 - 10:09
 0  1
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira ® (adalimumab)
Read More

Tags:

Previous Article

Forrester Announces Full Conference Agenda For CX Summit EMEA 2024

Next Article

Tabletop Tactics Selects Edgio to Deliver Premium Video Content Globally

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Kgaogelo Matshwi
Kgaogelo Matshwi

Related Posts

Deepfakes, AI-Manipulated Audio, and Hijacked Social Media Surge in 2024

Deepfakes, AI-Manipulated Audio, and Hijacked Social Me...

Kgaogelo Matshwi May 14, 2024  0  0

New York Community Bancorp, Inc. Bolsters Executive Team with Four Strategic Appointments

New York Community Bancorp, Inc. Bolsters Executive Tea...

Kgaogelo Matshwi Apr 13, 2024  0  2

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, Sharecare, and GoodRx and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Clas...

Kgaogelo Matshwi Apr 29, 2024  0  2